NCT04971304View on ClinicalTrials.gov

Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars

CompletedOBSERVATIONAL
Enrollment

16,506

Participants

Timeline

Start Date

March 1, 2015

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions
Cancer, BreastCancer, LungCancer of ColonCancer of PancreasCancer, OvarianLymphoma, Non-Hodgkin
Interventions
DRUG

Receipt of granulocyte-colony stimulating factor

Receipt of originator or biosimilar

All Listed Sponsors
collaborator

Harvard Pilgrim Health Care

OTHER

collaborator

HealthPartners Institute

OTHER

lead

Catherine M. Lockhart

OTHER

NCT04971304 - Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars | Biotech Hunter | Biotech Hunter